Mesoblast Change To Account Receivables from 2010 to 2025

MESO Stock  USD 12.11  1.19  8.95%   
Mesoblast Change To Account Receivables yearly trend continues to be very stable with very little volatility. Change To Account Receivables is likely to grow to about -13.2 M this year. During the period from 2010 to 2025, Mesoblast Change To Account Receivables quarterly data regression pattern had sample variance of 40.7 T and median of  140,000. View All Fundamentals
 
Change To Account Receivables  
First Reported
2013-03-31
Previous Quarter
M
Current Value
8.8 M
Quarterly Volatility
6.1 M
 
Yuan Drop
 
Covid
Check Mesoblast financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Mesoblast's main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.8 M, Interest Expense of 24.9 M or Selling General Administrative of 20.5 M, as well as many indicators such as Price To Sales Ratio of 122, Dividend Yield of 0.0 or PTB Ratio of 1.5. Mesoblast financial statements analysis is a perfect complement when working with Mesoblast Valuation or Volatility modules.
  
Check out the analysis of Mesoblast Correlation against competitors.
To learn how to invest in Mesoblast Stock, please use our How to Invest in Mesoblast guide.

Latest Mesoblast's Change To Account Receivables Growth Pattern

Below is the plot of the Change To Account Receivables of Mesoblast over the last few years. It is Mesoblast's Change To Account Receivables historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Mesoblast's overall financial position and show how it may be relating to other accounts over time.
Change To Account Receivables10 Years Trend
Slightly volatile
   Change To Account Receivables   
       Timeline  

Mesoblast Change To Account Receivables Regression Statistics

Arithmetic Mean(2,293,489)
Geometric Mean1,728,837
Coefficient Of Variation(278.25)
Mean Deviation4,940,984
Median140,000
Standard Deviation6,381,656
Sample Variance40.7T
Range20.4M
R-Value(0.71)
Mean Square Error21.6T
R-Squared0.50
Significance0
Slope(952,063)
Total Sum of Squares610.9T

Mesoblast Change To Account Receivables History

2025-13.2 M
2024-13.9 M
2023-15.5 M
2022-118 K
2021140 K
2020-1.7 M
2019890 K

About Mesoblast Financial Statements

Mesoblast investors utilize fundamental indicators, such as Change To Account Receivables, to predict how Mesoblast Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Change To Account Receivables-13.9 M-13.2 M
When determining whether Mesoblast offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Mesoblast's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Mesoblast Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Mesoblast Stock:
Check out the analysis of Mesoblast Correlation against competitors.
To learn how to invest in Mesoblast Stock, please use our How to Invest in Mesoblast guide.
You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Mesoblast. If investors know Mesoblast will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Mesoblast listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.05)
Revenue Per Share
0.06
Quarterly Revenue Growth
(0.41)
Return On Assets
(0.05)
Return On Equity
(0.18)
The market value of Mesoblast is measured differently than its book value, which is the value of Mesoblast that is recorded on the company's balance sheet. Investors also form their own opinion of Mesoblast's value that differs from its market value or its book value, called intrinsic value, which is Mesoblast's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Mesoblast's market value can be influenced by many factors that don't directly affect Mesoblast's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Mesoblast's value and its price as these two are different measures arrived at by different means. Investors typically determine if Mesoblast is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Mesoblast's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.